Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Shaping the regulation of the p53 mRNA tumour suppressor: the co-evolution of genetic signatures

K. Karakostis, R. Fåhraeus,

. 2019 ; 19 (1) : 915. [pub] 20190913

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005909

Structured RNA regulatory motifs exist from the prebiotic stages of the RNA world to the more complex eukaryotic systems. In cases where a functional RNA structure is within the coding sequence a selective pressure drives a parallel co-evolution of the RNA structure and the encoded peptide domain. The p53-MDM2 axis, describing the interactions between the p53 tumor suppressor and the MDM2 E3 ubiquitin ligase, serves as particularly useful model revealing how secondary RNA structures have co-evolved along with corresponding interacting protein motifs, thus having an impact on protein - RNA and protein - protein interactions; and how such structures developed signal-dependent regulation in mammalian systems. The p53(BOX-I) RNA sequence binds the C-terminus of MDM2 and controls p53 synthesis while the encoded peptide domain binds MDM2 and controls p53 degradation. The BOX-I peptide domain is also located within p53 transcription activation domain. The folding of the p53 mRNA structure has evolved from temperature-regulated in pre-vertebrates to an ATM kinase signal-dependent pathway in mammalian cells. The protein - protein interaction evolved in vertebrates and became regulated by the same signaling pathway. At the same time the protein - RNA and protein - protein interactions evolved, the p53 trans-activation domain progressed to become integrated into a range of cellular pathways. We discuss how a single synonymous mutation in the BOX-1, the p53(L22 L), observed in a chronic lymphocyte leukaemia patient, prevents the activation of p53 following DNA damage. The concepts analysed and discussed in this review may serve as a conceptual mechanistic paradigm of the co-evolution and function of molecules having roles in cellular regulation, or the aetiology of genetic diseases and how synonymous mutations can affect the encoded protein.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005909
003      
CZ-PrNML
005      
20200525093327.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-019-6118-y $2 doi
035    __
$a (PubMed)31519161
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Karakostis, Konstantinos $u Université Paris 7, INSERM UMR 1131, 27 Rue Juliette Dodu, 75010, Paris, France. chem898@yahoo.gr.
245    10
$a Shaping the regulation of the p53 mRNA tumour suppressor: the co-evolution of genetic signatures / $c K. Karakostis, R. Fåhraeus,
520    9_
$a Structured RNA regulatory motifs exist from the prebiotic stages of the RNA world to the more complex eukaryotic systems. In cases where a functional RNA structure is within the coding sequence a selective pressure drives a parallel co-evolution of the RNA structure and the encoded peptide domain. The p53-MDM2 axis, describing the interactions between the p53 tumor suppressor and the MDM2 E3 ubiquitin ligase, serves as particularly useful model revealing how secondary RNA structures have co-evolved along with corresponding interacting protein motifs, thus having an impact on protein - RNA and protein - protein interactions; and how such structures developed signal-dependent regulation in mammalian systems. The p53(BOX-I) RNA sequence binds the C-terminus of MDM2 and controls p53 synthesis while the encoded peptide domain binds MDM2 and controls p53 degradation. The BOX-I peptide domain is also located within p53 transcription activation domain. The folding of the p53 mRNA structure has evolved from temperature-regulated in pre-vertebrates to an ATM kinase signal-dependent pathway in mammalian cells. The protein - protein interaction evolved in vertebrates and became regulated by the same signaling pathway. At the same time the protein - RNA and protein - protein interactions evolved, the p53 trans-activation domain progressed to become integrated into a range of cellular pathways. We discuss how a single synonymous mutation in the BOX-1, the p53(L22 L), observed in a chronic lymphocyte leukaemia patient, prevents the activation of p53 following DNA damage. The concepts analysed and discussed in this review may serve as a conceptual mechanistic paradigm of the co-evolution and function of molecules having roles in cellular regulation, or the aetiology of genetic diseases and how synonymous mutations can affect the encoded protein.
650    _2
$a zvířata $7 D000818
650    _2
$a stanovení celkové genové exprese $7 D020869
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a nádory $x genetika $x metabolismus $x patologie $7 D009369
650    _2
$a vazba proteinů $7 D011485
650    _2
$a interakční proteinové domény a motivy $7 D054730
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a proteiny vázající RNA $x metabolismus $7 D016601
650    _2
$a transkriptom $7 D059467
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
650    _2
$a nádorové supresorové proteiny $x genetika $x metabolismus $7 D025521
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Fåhraeus, Robin $u Université Paris 7, INSERM UMR 1131, 27 Rue Juliette Dodu, 75010, Paris, France. Department of Medical Biosciences, Umea University, SE-90185, Umea, Sweden. RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 19, č. 1 (2019), s. 915
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31519161 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200525093327 $b ABA008
999    __
$a ok $b bmc $g 1524767 $s 1095965
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 1 $d 915 $e 20190913 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...